Article
Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee
16 Jul 2015
Abstract excerpt
No abstract is available from the source.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.